Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | XBP1 | P17861 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3728417 | 1.00 | CA12 (0.42) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL3725618 | 1.00 | CA12 (0.42) | CA12CA14DGAT1CA1CA2 | |
| Hydrochloric Acid SCHEMBL31645354 | 0.98 | CA12 (0.41) | CA12CA14DGAT1CA1CA2 | |
| Hydrochloric Acid SCHEMBL18342541 | 0.98 | CA12 (0.41) | CA12CA14DGAT1CA1CA2 | |
| Hydrochloric Acid SCHEMBL5753572 | 0.98 | CA12 (0.41) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL30902877 | 0.90 | CA12 (0.37) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL5801336 | 0.88 | CA14 (0.46) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL13223287 | 0.86 | CA12 (0.37) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL3185669 | 0.81 | CA12 (0.42) | CA12CA14DGAT1CA1CA2 | |
| SCHEMBL10892359 | 0.81 | CA12 (0.42) | CA12CA14DGAT1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023178299-A1 | PRODRUGS OF GANAXOLONE | MARINUS PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| EP-3778602-B1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC (US) | 2023-07-12 | — | — | EP | disclosed |
| EP-4163284-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| WO-2021085636-A1 | REACTION AGENT FOR AMIDE REACTIONS AND AMIDE COMPOUND PRODUCTION METHOD USING SAME | 学校法人中部大学 | 2021-05-06 | — | — | WO | disclosed |
| EP-3778602-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3325482-B1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3653628-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2020-05-20 | — | — | EP | disclosed |
| EP-3325483-B1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC (US) | 2019-10-02 | — | — | EP | disclosed |
| CN-104603146-B | Cyclic peptide compound and its purposes as medicine | 诺华股份有限公司 | 2018-01-02 | — | — | CN | disclosed |
| US-9566312-B2 | Cyclic peptides and use as medicines | NOVARTIS AG (CH) | 2017-02-14 | — | — | US | disclosed |
| CN-104603146-A | Cyclic peptides and use as medicines | NOVARTIS AG | 2015-05-06 | — | — | CN | disclosed |
| CN-103254213-B | Preparation method of maytenin-like ester and composition used in method | BIO THERA SOLUTIONS LTD | 2015-02-25 | — | — | CN | disclosed |
| US-20140134132-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | NOVARTIS AG (CH) | 2014-05-15 | — | — | US | disclosed |
| US-8338565-B2 | Macrocyclic compounds for inhibition of tumor necrosis factor alpha | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE THERAPEUTICS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| US-20090181958-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-07-16 | — | — | US | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7429597-B2 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2008-09-30 | — | — | US | disclosed |
| CN-1950328-A | Phenyl indan derivatives | LUNDBECK & CO AS H (DK) | 2007-04-18 | — | — | CN | disclosed |
| US-20040176603-A1 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176603-A1 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | F11, F12, F2 | CA12 2253/4885CA14 2474/4885DGAT1 4022/4885 |
| US-20140134132-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | PPIF, VIP, FKBP1B | CA12 2451/4885CA14 3090/4885DGAT1 4859/4885 |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | TNF, CD40, TNFRSF1A | CA12 2459/4885CA14 2107/4885DGAT1 2103/4885 |
| US-20090181958-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | F12, F11, F2 | CA12 2030/4885CA14 2790/4885DGAT1 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.